How many 8-K filings has Revelation Biosciences, Inc. filed?

Revelation Biosciences, Inc. (REVBW) has 29 8-K (Current Event Report) filings on record, spanning Jan 2024 to Dec 2025.

What is a 8-K filing?

A 8-K is an SEC filing known as "Current Event Report." Filed to announce significant events or material changes such as acquisitions, executive departures, earnings announcements, or bankruptcy filings.

Where can I read Revelation Biosciences, Inc. 8-K filings in plain English?

ReadTheFiling provides AI-powered plain-English summaries of all Revelation Biosciences, Inc. 8-K filings, including risk assessment, sentiment analysis, and key financial figures.

Revelation Biosciences, Inc. (REVBW) — 8-K Filings

All 8-K filings from Revelation Biosciences, Inc.. Browse 29 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (29)

Revelation Biosciences Files 8-K on Security Holder Rights — Dec 3, 2025 Risk: medium
Revelation Biosciences, Inc. filed an 8-K on December 3, 2025, reporting material modifications to security holder rights and submitting matters to a vote. The
Revelation Biosciences Files 8-K — Oct 29, 2025 Risk: low
Revelation Biosciences, Inc. filed an 8-K on October 29, 2025, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly
Revelation Biosciences Files 8-K — Oct 15, 2025 Risk: low
Revelation Biosciences, Inc. filed an 8-K on October 15, 2025, reporting on Regulation FD disclosures and financial statements. The company, formerly known as P
Revelation Biosciences Enters Material Agreement, Reports Equity Sales — Sep 15, 2025 Risk: medium
Revelation Biosciences, Inc. announced on September 11, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sa
Revelation Biosciences Files 8-K — Sep 9, 2025 Risk: low
Revelation Biosciences, Inc. filed an 8-K on September 9, 2025, reporting on other events and financial statements. The company, formerly known as Petra Acquisi
Revelation Biosciences Files 8-K on Security Holder Rights — Jul 9, 2025 Risk: medium
Revelation Biosciences, Inc. filed an 8-K on July 9, 2025, reporting material modifications to security holder rights and other events as of July 7, 2025. The f
Revelation Biosciences Files 8-K on Shareholder Votes and Other Events — Jun 25, 2025 Risk: low
Revelation Biosciences, Inc. filed an 8-K on June 25, 2025, reporting on matters submitted to a vote of security holders and other events that occurred on June
Revelation Biosciences Files 8-K on Warrant Agreement — Jun 4, 2025 Risk: medium
Revelation Biosciences, Inc. announced on May 28, 2025, a material definitive agreement related to its redeemable warrants. The company, formerly known as Petra
Revelation Biosciences Announces Board Changes — May 28, 2025 Risk: medium
Revelation Biosciences, Inc. announced on May 23, 2025, a change in its board of directors. Specifically, the company reported the departure of certain officers
Revelation Biosciences Files 8-K on Redeemable Warrants — Mar 17, 2025 Risk: low
On March 17, 2025, Revelation Biosciences, Inc. filed an 8-K report. The filing indicates that the company's redeemable warrants, each exercisable for 1/16800th
Revelation Biosciences 8-K Filing — Feb 24, 2025 Risk: low
Revelation Biosciences, Inc. filed an 8-K on February 24, 2025, reporting an event on February 19, 2025. The filing indicates the company's former name was Petr
Revelation Biosciences Files 8-K — Feb 11, 2025 Risk: low
Revelation Biosciences, Inc. filed an 8-K on February 11, 2025, reporting on events as of February 10, 2025. The filing primarily concerns financial statements
Revelation Biosciences Files 8-K on Security Holder Rights — Jan 30, 2025 Risk: medium
Revelation Biosciences, Inc. filed an 8-K on January 30, 2025, reporting material modifications to security holder rights and amendments to its articles of inco
Revelation Biosciences Files 8-K — Jan 21, 2025 Risk: low
Revelation Biosciences, Inc. filed an 8-K on January 21, 2025, reporting on events that occurred on January 17, 2025. The filing includes information on submiss
Revelation Biosciences Faces Delisting Concerns — Jan 7, 2025 Risk: high
Revelation Biosciences, Inc. filed an 8-K on January 7, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The co
Revelation Biosciences Files 8-K on Warrants — Dec 12, 2024 Risk: medium
Revelation Biosciences, Inc. filed an 8-K on December 12, 2024, reporting on other events and financial statements. The company, formerly known as Petra Acquisi
Revelation Biosciences Files 8-K: Material Agreement & Equity Changes — Dec 6, 2024 Risk: medium
Revelation Biosciences, Inc. announced on December 3, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sale
Revelation Biosciences Faces Delisting Concerns — Oct 21, 2024 Risk: high
Revelation Biosciences, Inc. filed an 8-K on October 21, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The c
Revelation Biosciences Files 8-K, Details Financials — Sep 27, 2024 Risk: low
Revelation Biosciences, Inc. filed an 8-K on September 27, 2024, reporting an event on September 24, 2024. The filing indicates the company's former name was Pe
Revelation Biosciences Enters Material Agreement, Reports Equity Sales — Aug 26, 2024 Risk: medium
Revelation Biosciences, Inc. announced on August 21, 2024, that it entered into a material definitive agreement. The company also reported on unregistered sales
Revelation Biosciences Faces Delisting Concerns — Aug 19, 2024 Risk: high
Revelation Biosciences, Inc. filed an 8-K on August 19, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard as of A
Revelation Biosciences Files 8-K — Aug 2, 2024 Risk: low
Revelation Biosciences, Inc. filed an 8-K on August 1, 2024, reporting on other events and financial statements. The company, formerly known as Petra Acquisitio
Revelation Biosciences Files 8-K — Jun 24, 2024 Risk: low
Revelation Biosciences, Inc. filed an 8-K on June 24, 2024, reporting other events and financial statements. The company, formerly known as Petra Acquisition In
Revelation Biosciences Files 8-K — May 16, 2024 Risk: low
Revelation Biosciences, Inc. filed an 8-K on May 15, 2024, reporting on matters submitted to a vote of security holders and filing financial statements and exhi
Revelation Biosciences Files 8-K — Mar 12, 2024 Risk: low
Revelation Biosciences, Inc. filed an 8-K on March 12, 2024, reporting on other events and financial statements. The company, formerly known as Petra Acquisitio
Revelation Biosciences Issues Warrants Exercisable at $12,075/Share — Feb 8, 2024 Risk: medium
On February 5, 2024, Revelation Biosciences, Inc. entered into a material definitive agreement to issue redeemable warrants, each exercisable for a 1/10,500th s
Revelation Biosciences Confirms Common Stock & Warrant Details — Jan 30, 2024
Revelation Biosciences, Inc. filed an 8-K on January 30, 2024, to disclose that its common stock, with a par value of $0.0001 per share, is registered on an exc
Revelation Biosciences Warrants Diluted 35-to-1; Exercise Price $40.25 — Jan 23, 2024
On January 22, 2024, Revelation Biosciences, Inc. filed an 8-K to report material modifications to the rights of its security holders and amendments to its Arti
REVELATION BIOSCIENCES Files 8-K on Shareholder Vote Matters — Jan 22, 2024
REVELATION BIOSCIENCES, INC. filed an 8-K on January 22, 2024, reporting an event that occurred on January 17, 2024. The filing indicates the submission of matt

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX